Literature DB >> 16391835

Late-onset and typical Huntington disease families from Crete have distinct genetic origins.

Eleonora Kartsaki1, Cleanthe Spanaki, Minas Tzagournissakis, Aphrodite Petsakou, Nicholas Moschonas, Marcy Macdonald, Andreas Plaitakis.   

Abstract

HD families in which late-onset occurs consistently in affected members are rare. The objectives of this work was to study such late-onset HD families encountered on Crete, and to trace their genetic origin. Nine late-onset HD kindreds (61 affected members) were studied along with two typical HD families (17 affected members). We genotyped 33 late-onset Cretan HD chromosomes, 9 Cretan typical HD chromosomes and 114 Cretan control chromosomes using 14 STR markers and 20 SNPs that map to 4p16.3. In contrast to the typical HD pedigrees, the late-onset HD families lacked anticipation and juvenile cases. The expanded CAG repeat (36-42 units) in these families remained either stable or it showed small increment instability, even when transmitted through the father. All late-onset HD chromosomes shared a conserved haplotype defined by the markers D4S95: 1090, D4S127: 157, rs362277: A, rs3025814: G, rs2530596: A that span a 0.277-Mb segment on 4p16.3. Coalescence analysis traced this haplotype to a founder who lived about 1000 years ago. In contrast, each of the two typical HD disease pedigrees derived from a different founder. Sequencing of a 5-kb DNA segment immediately upstream of the HD gene revealed a novel single nucleotide polymorphism at -1757 bp relative to the translation start site, which was more prevalent in Cretan than in North American chromosomes. All late-onset HD families on Crete arose from a common founder with the disease's mutation evolving over the centuries via small-increment instability. These findings suggest that cis-acting factors may be operational.

Entities:  

Mesh:

Year:  2006        PMID: 16391835

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

1.  Comparison of mid-age-onset and late-onset Huntington's disease in Finnish patients.

Authors:  Jussi O T Sipilä; Tommi Kauko; Markku Päivärinta; Kari Majamaa
Journal:  J Neurol       Date:  2017-08-28       Impact factor: 4.849

2.  Huntington disease mutation in Venezuela: age of onset, haplotype analyses and geographic aggregation.

Authors:  Irene Paradisi; Alba Hernández; Sergio Arias
Journal:  J Hum Genet       Date:  2007-12-22       Impact factor: 3.172

3.  Late onset Huntington Disease: clinical and genetic characteristics of 34 cases.

Authors:  Hillary Lipe; Thomas Bird
Journal:  J Neurol Sci       Date:  2008-10-31       Impact factor: 3.181

4.  CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup.

Authors:  Simon C Warby; Alexandre Montpetit; Anna R Hayden; Jeffrey B Carroll; Stefanie L Butland; Henk Visscher; Jennifer A Collins; Alicia Semaka; Thomas J Hudson; Michael R Hayden
Journal:  Am J Hum Genet       Date:  2009-02-26       Impact factor: 11.025

5.  Correlation of CAG repeat length between the maternal and paternal allele of the Huntingtin gene: evidence for assortative mating.

Authors:  Peg Nopoulos; Eric A Epping; Tom Wassink; Bradley L Schlaggar; Joel Perlmutter
Journal:  Behav Brain Funct       Date:  2011-10-18       Impact factor: 3.759

6.  Correlation of inter-locus polyglutamine toxicity with CAG•CTG triplet repeat expandability and flanking genomic DNA GC content.

Authors:  Colm E Nestor; Darren G Monckton
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

7.  Oromandibular dyskinesia as the initial manifestation of late-onset huntington disease.

Authors:  Dong-Seok Oh; Eun-Seon Park; Seong-Min Choi; Byeong-Chae Kim; Myeong-Kyu Kim; Ki-Hyun Cho
Journal:  J Mov Disord       Date:  2011-10-30

8.  Bioinformatic analysis of microRNA expression in Huntington's disease.

Authors:  Xiaoyu Dong; Shuyan Cong
Journal:  Mol Med Rep       Date:  2018-06-29       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.